Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T19:02:07.713Z.
Calculation as of: 2026-10-06T19:02:07.713Z.
Quote observation: 2026-10-06T18:59:59.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 443dbef5a4958c6c8665db428659f78ed614b233762584452a295f0fd6fa7086
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
Indaptus Therapeutics, Inc.
Market Cap
$291.03M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$286.40M
EV/EBITDA Ratio
N/A
TTM Avg
18.83x
3Y Avg
18.83x
5Y Avg
18.83x
Market Cap
$284.62M
EV/EBITDA Ratio
N/A
TTM Avg
10.42x
3Y Avg
23.40x
5Y Avg
23.40x
Market Cap
$292.43M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$284.78M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$282.68M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$299.07M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Indaptus Therapeutics, Inc. (INDP) | $291.03M | N/A | N/A | N/A | N/A |
| Abeona Therapeutics Inc. (ABEO)vs › | $286.40M | N/A | 18.83x | 18.83x | 18.83x |
| Sagimet Biosciences Inc. (SGMT)vs › | $286.07M | N/A | N/A | N/A | N/A |
| Aurora Cannabis Inc. (ACB)vs › | $284.62M | N/A | 10.42x | 23.40x | 23.40x |
| Larimar Therapeutics, Inc. (LRMR)vs › | $292.43M | N/A | N/A | N/A | N/A |
| BridgeBio Oncology Therapeutics Inc. (BBOT)vs › | $284.78M | N/A | N/A | N/A | N/A |
| Fulcrum Therapeutics, Inc. (FULC)vs › | $282.68M | N/A | N/A | N/A | N/A |
| Standard BioTools Inc. (LAB)vs › | $281.54M | N/A | N/A | N/A | N/A |
| Mobia Medical, Inc. Common Stock (MOBI)vs › | $299.07M | N/A | N/A | N/A | N/A |
| TriSalus Life Sciences, Inc. (TLSI)vs › | $271.54M | N/A | N/A | N/A | N/A |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
